Trials / Recruiting
RecruitingNCT07199088
Comparative Efficacy and Safety of Acetazolamide Versus Metolazone as an Adjunct to Standard Therapy in Patients With Acute Decompensated Heart Failure
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 320 (estimated)
- Sponsor
- University of Health Sciences Lahore · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This clinical trial aims to compare the efficacy and safety of acetazolamide versus metolazone as adjunctive treatments to standard therapy in patients with acute decompensated heart failure (ADHF). ADHF is a life-threatening condition, and current treatments often involve loop diuretics to alleviate volume overload. This study will assess the added benefit of acetazolamide and metolazone in improving decongestion, reducing hospital stays, and preventing complications such as renal dysfunction or electrolyte imbalances. Participants will be randomized to receive either acetazolamide or metolazone in addition to standard diuretic therapy. The trial will evaluate primary outcomes including successful decongestion, in-hospital mortality, and length of hospital stay, with secondary outcomes focusing on renal function, electrolyte disturbances, and overall safety. The study is conducted at Bahawal Victoria Hospital, Bahawalpur, and aims to provide valuable insights into the management of ADHF, especially in the Pakistani population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Acetazolamide | A carbonic anhydrase inhibitor, 500 mg orally once a day as an adjunct to loop diuretics for enhancing diuresis and improving decongestion in ADHF patients. |
| OTHER | Metolazone | A thiazide-like diuretic, 5 mg orally once a day as an adjunct to loop diuretics for enhancing diuresis and improving decongestion in ADHF patients. |
Timeline
- Start date
- 2025-10-11
- Primary completion
- 2026-10-16
- Completion
- 2026-10-30
- First posted
- 2025-09-30
- Last updated
- 2025-10-03
Locations
1 site across 1 country: Pakistan
Source: ClinicalTrials.gov record NCT07199088. Inclusion in this directory is not an endorsement.